Zygolide becomes first FDA-approved generic pergolide for horses

CURRENT BRIEF VERSION: Dechra’s Zygolide, a pergolide tablet for horses with pituitary pars intermedia dysfunction, or PPID, won FDA approval on December 19, 2025, and the agency publicly announced it on January 9, 2026, as the first generic approved for control of clinical signs associated with equine Cushing’s disease. FDA said Zygolide is bioequivalent to Prascend, the long-established brand product first approved in 2011. Promotional materials highlighted practical features aimed at daily use, including peppermint flavoring and scored tablets for dose adjustment, and The Horse carousel framed the launch with brand-forward messaging such as “Rediscover the partnership with Zygolide.” (fda.gov; thehorse.com)

Why it matters: For equine veterinarians, the arrival of a first generic pergolide option could improve long-term adherence for horses that need chronic PPID management, especially if cost or tablet administration has been a barrier for pet parents and barns. Labeling shows a starting dose of 2 mcg/kg once daily, with titration up to 4 mcg/kg, and the product insert notes that 47 of 113 horses in the effectiveness database needed a dose increase by Day 90. Clinicians will also want to counsel handlers on safety: tablets should not be crushed because of human exposure concerns, and decreased appetite was the most common adverse event in the field study, reported in 40 of 122 horses. (dechra-us.com)

What to watch: Watch for early uptake in equine practice, price competition versus branded pergolide, and whether Dechra or distributors publish more real-world adherence or access data in 2026. The Horse ad placements suggest Dechra is backing the launch with visible awareness marketing, even if those carousel slides add little clinical detail beyond the broader promotional push. (skillmanvet.com; thehorse.com)